These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 18704280)

  • 21. Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in -thalassemia major patients.
    Pantalone GR; Maggio A; Vitrano A; Capra M; Cuccia L; Gagliardotto F; Filosa A; Romeo MA; Magnano C; Caruso V; Argento C; Gerardi C; Campisi S; Violi P; Malizia R; Cianciulli P; Rizzo M; D'Ascola DG; Quota A; Prossomariti L; Fidone C; Rigano P; Pepe A; D'Amico G; Morabito A; Gluud C
    Hemoglobin; 2011; 35(3):206-16. PubMed ID: 21599433
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone.
    Lai ME; Grady RW; Vacquer S; Pepe A; Carta MP; Bina P; Sau F; Cianciulli P; Maggio A; Galanello R; Farci P
    Blood Cells Mol Dis; 2010 Aug; 45(2):136-9. PubMed ID: 20678715
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom.
    Karnon J; Tolley K; Oyee J; Jewitt K; Ossa D; Akehurst R
    Curr Med Res Opin; 2008 Jun; 24(6):1609-21. PubMed ID: 18439348
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-utility analysis of oral deferasirox versus infusional deferoxamine in transfusion-dependent β-thalassemia patients.
    Keshtkaran A; Javanbakht M; Salavati S; Mashayekhi A; Karimi M; Nuri B
    Transfusion; 2013 Aug; 53(8):1722-9. PubMed ID: 23241074
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia.
    Tsironi M; Assimakopoulos G; Polonofi K; Rigaki K; Aessopos A
    Hemoglobin; 2008; 32(1-2):29-34. PubMed ID: 18274980
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
    Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined chelation therapy in thalassemia major with deferiprone and desferrioxamine: a retrospective study.
    Ricchi P; Ammirabile M; Spasiano A; Costantini S; Cinque P; Di Matola T; Pagano L; Prossomariti L
    Eur J Haematol; 2010 Jul; 85(1):36-42. PubMed ID: 20331740
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined iron chelation therapy.
    Galanello R; Agus A; Campus S; Danjou F; Giardina PJ; Grady RW
    Ann N Y Acad Sci; 2010 Aug; 1202():79-86. PubMed ID: 20712777
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial.
    Maggio A; Vitrano A; Capra M; Cuccia L; Gagliardotto F; Filosa A; Romeo MA; Magnano C; Caruso V; Argento C; Gerardi C; Campisi S; Violi P; Malizia R; Cianciulli P; Rizzo M; D'Ascola DG; Quota A; Prossomariti L; Fidone C; Rigano P; Pepe A; D'Amico G; Morabito A; Gluud C
    Br J Haematol; 2009 Apr; 145(2):245-54. PubMed ID: 19236376
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta-thalassaemia major.
    Farmaki K; Angelopoulos N; Anagnostopoulos G; Gotsis E; Rombopoulos G; Tolis G
    Br J Haematol; 2006 Aug; 134(4):438-44. PubMed ID: 16822284
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Objectives and mechanism of iron chelation therapy.
    Hershko C; Link G; Konijn AM; Cabantchik ZI
    Ann N Y Acad Sci; 2005; 1054():124-35. PubMed ID: 16339658
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
    Saliba AN; El Rassi F; Taher AT
    Expert Rev Hematol; 2016; 9(2):151-68. PubMed ID: 26613264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term persistency and costs associated with the use of iron chelation therapies in the treatment of Sickle cell disease within Medicaid programs.
    Armstrong EP; Skrepnek GH; Sasane M; Snodgrass SM; Ballas SK
    J Med Econ; 2013; 16(1):10-8. PubMed ID: 22947171
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in the prevention and treatment are changing thalassemia from a fatal to a chronic disease. experience from a Cyprus model and its use as a paradigm for future applications.
    Kolnagou A; Kontoghiorghes GJ
    Hemoglobin; 2009; 33(5):287-95. PubMed ID: 19814674
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A time-cost augmented economic evaluation of oral deferasirox versus infusional deferoxamine [corrected] for patients with iron overload in South Korea.
    Kim J; Kim Y
    Value Health; 2009; 12 Suppl 3():S78-81. PubMed ID: 20586988
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia.
    Cappellini MD; Bejaoui M; Agaoglu L; Porter J; Coates T; Jeng M; Lai ME; Mangiagli A; Strauss G; Girot R; Watman N; Ferster A; Loggetto S; Abish S; Cario H; Zoumbos N; Vichinsky E; Opitz H; Ressayre-Djaffer C; Abetz L; Rofail D; Baladi JF
    Clin Ther; 2007 May; 29(5):909-917. PubMed ID: 17697909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Iron chelation therapy for patients with sickle cell disease and iron overload.
    Inati A; Khoriaty E; Musallam KM; Taher AT
    Am J Hematol; 2010 Oct; 85(10):782-6. PubMed ID: 20721892
    [No Abstract]   [Full Text] [Related]  

  • 38. Overview of iron chelation therapy with desferrioxamine and deferiprone.
    Cappellini MD; Musallam KM; Taher AT
    Hemoglobin; 2009; 33 Suppl 1():S58-69. PubMed ID: 20001633
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients.
    Kontoghiorghes GJ
    Hemoglobin; 2009; 33(5):332-8. PubMed ID: 19814679
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral iron chelating therapy. A single center interim report on deferiprone (L1) in thalassemia.
    Mazza P; Amurri B; Lazzari G; Masi C; Palazzo G; Spartera MA; Giua R; Sebastio AM; Suma V; De Marco S; Semeraro F; Moscogiuri R
    Haematologica; 1998 Jun; 83(6):496-501. PubMed ID: 9676021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.